How to Help Your Patients Save Money on Humatin: A Provider's Guide to Savings Programs

For any clinician who has prescribed Humatin (paromomycin), the drug's effectiveness is not in question. The question is whether patients can actually afford it. With retail prices exceeding $3,000 to $6,000 for a single treatment course and the generic discontinued, Humatin is among the most expensive antibiotic prescriptions your patient may ever receive. This guide is designed to help providers navigate the savings landscape and ensure patients have a clear path to access.

Understanding the Cost Landscape

As of 2026, Humatin (brand-name paromomycin sulfate 250 mg capsules) retails for approximately:

• $6,150 average retail for a 42-capsule course (GoodRx data)
• $3,168 retail for 21 capsules; ~$2,702 with SingleCare coupon
• $12,475 per 100 capsules at some pharmacy pricing (Drugs.com)

The generic paromomycin sulfate capsule has been discontinued, eliminating the pricing competition that would normally lower these costs. The result is that uninsured or underinsured patients face catastrophic out-of-pocket costs for a short-course antibiotic treatment for a curable infection. This is not a theoretical concern — a 2026 publication in Open Forum Infectious Diseases documented the barrier that Humatin's exorbitant cost creates for underserved patients, highlighting the need for providers to be proactive about connecting patients to assistance programs.

Tool 1: Humatin TotalCare Patient Assistance Program

The Humatin TotalCare program from Waylis Therapeutics is the most impactful savings tool available for uninsured or underinsured patients. The program can provide Humatin at low or no cost to eligible patients. Here's what providers need to know to use it effectively:

• Contact: 844-200-7910 (Waylis Therapeutics)
• Eligibility: Income-based. Typically requires demonstration that the patient is uninsured, underinsured, or cannot afford the medication. Specific income thresholds apply.
• Documentation needed: Typically requires a completed enrollment form, proof of income, a signed prescription, and prescriber information. The burden of paperwork is significant — consider assigning a nurse or MA to manage PAP enrollments.
• Timeline: Processing can take days to weeks. For patients who need treatment urgently, explore bridging options (prior auth, sample, or alternative treatment) while the PAP application processes.

One published case study noted that while programs like Humatin TotalCare aim to improve access, "strict eligibility criteria and complex enrollment processes are often insurmountable barriers" — underscoring the importance of provider-side facilitation. Patient literacy and time constraints can make independent navigation impossible for many patients.

Tool 2: Insurance Prior Authorization — Getting It Right the First Time

For insured patients, prior authorization is mandatory for almost all commercial insurance plans covering Humatin. A robust, well-documented PA submission dramatically increases the chance of first-attempt approval and reduces treatment delays. Build a PA checklist into your workflow for Humatin:

• Confirmed diagnosis: stool PCR or antigen test for E. histolytica; stool O&P report for other parasites
• Prescriber documentation: specialty (ID, GI) or attestation of consultation with specialist — required by many PBM criteria
• ICD-10 codes: A06.0 (acute amebic dysentery), A06.1 (chronic intestinal amebiasis), A06.9 (amebiasis unspecified)
• Intended dose and duration: 25-35 mg/kg/day in 3 divided doses with meals for 5-10 days
• Clinical rationale for paromomycin specifically (luminal clearance, pregnancy, allergy/intolerance to alternatives)

If the initial PA is denied, file an appeal immediately. PA appeal success rates are higher when the clinical documentation is complete and the treating specialist makes the case directly. Peer-to-peer review with the insurance medical director is often available and can be pivotal for complex cases.

Tool 3: Copay Assistance for Commercially Insured Patients

For commercially insured patients with high copays or coinsurance, check whether Waylis Therapeutics offers a copay assistance card or copay program. These programs can reduce patient copays to as low as $5-$20 per prescription for eligible patients. They are typically not available to patients on federal programs (Medicare, Medicaid) but apply to most commercial plans. Contact Waylis Therapeutics at 844-200-7910 for current copay program availability and terms.

Tool 4: Hospital Financial Assistance and Safety Net Programs

Hospital systems that treat underserved populations often have charity care or financial assistance programs for outpatient medications. If you practice at a hospital-affiliated infectious disease clinic, your social work or patient financial services team may be able to provide subsidized Humatin to qualifying patients. Systems like Harris Health in Houston, for example, have been documented subsidizing specialty antiparasitic drugs for low-income patients. Knowing your institution's resources — and making a warm handoff to the financial counselor — can be the difference between a patient completing treatment and abandoning it.

Tool 5: medfinder for Providers — Finding the Best-Priced Available Pharmacy

Price varies significantly across pharmacies for Humatin, and not all pharmacies are even willing to stock or order it. medfinder.com/providers can search pharmacies on behalf of your patient to find which ones have the drug available — and at what price. Directing patients to the most accessible pharmacy rather than the nearest chain saves them time and ensures they can fill the prescription without multiple failed attempts.

When Cost Is an Absolute Barrier: Considering Clinical Alternatives

If a patient genuinely cannot access Humatin — either due to cost, insurance denial after appeal, or geographic unavailability — a clinical pivot may be necessary. For intestinal amebiasis:

• Iodoquinol (650 mg TID x 20 days) is a luminal amebicide alternative, though also with limited U.S. availability
• For hepatic encephalopathy, lactulose (first-line) and rifaximin (preferred for secondary prevention) are both well-supported alternatives to paromomycin and widely available
• For off-label indications (giardiasis, cryptosporidiosis), first-line options typically include metronidazole, tinidazole, or nitazoxanide — all more accessible and affordable

Systemic Advocacy: Documenting Barriers

Every time a patient is denied affordable access to Humatin, document it. Note the prescribing intent, insurance denial, access barriers, and any alternative treatment taken. This data serves two purposes: it supports individual appeals, and it contributes to the broader evidence base that researchers and policymakers need to address the structural market failure affecting niche antiparasitic drugs in the U.S. Infectious disease society advocacy groups (IDSA, HIVMA) are actively engaged in this issue.